Company Overview - Aibo Medical closed at 75.72 yuan on August 1, with a decline of 1.82%, resulting in a rolling PE ratio of 38.74 times and a total market capitalization of 14.644 billion yuan [1] - The company ranks 80th in the medical device industry, which has an average PE ratio of 53.65 times and a median of 37.22 times [1] Shareholder Information - As of March 31, 2025, Aibo Medical had 9,729 shareholders, a decrease of 94 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Aibo Medical focuses on the independent research, production, sales, and related services of ophthalmic medical devices, with key products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] Financial Performance - In the latest quarterly report for Q1 2025, Aibo Medical reported revenue of 357 million yuan, a year-on-year increase of 15.07%, while net profit was 92.5581 million yuan, reflecting a year-on-year decrease of 10.05%, with a gross profit margin of 64.60% [1]

Company Overview - Aibo Medical closed at 81.07 yuan, up 1.58%, with a rolling PE ratio of 40.65 times and a total market value of 15.366 billion yuan [1] - The company ranks 83rd in the medical device industry, which has an average PE ratio of 49.02 times and a median of 36.25 times [1] Shareholder Information - As of March 31, 2025, Aibo Medical had 9,729 shareholders, a decrease of 94 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Aibo Medical focuses on the independent research, production, sales, and related services of ophthalmic medical devices, with main products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] Financial Performance - In the first quarter of 2025, Aibo Medical reported revenue of 357 million yuan, a year-on-year increase of 15.07%, and a net profit of 92.5581 million yuan, a year-on-year decrease of 10.05%, with a gross profit margin of 64.60% [1]

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Aibo Medical, indicating a decline in stock price and a comparison with industry averages [1] - Aibo Medical's closing stock price is 79.25 yuan, down 2.92%, with a rolling PE ratio of 39.73 times and a total market capitalization of 15.021 billion yuan [1] - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Aibo Medical at the 82nd position in the industry ranking [1] Group 2 - As of the first quarter of 2025, 67 institutions hold shares in Aibo Medical, including 62 funds, with a total shareholding of 67.74 million shares valued at 6.637 billion yuan [1] - Aibo Medical specializes in the research, development, production, sales, and related services of ophthalmic medical devices, with key products including artificial lenses and other vision care products [1] - The latest financial results for the first quarter of 2025 show Aibo Medical achieving a revenue of 357 million yuan, a year-on-year increase of 15.07%, while net profit was 92.558 million yuan, reflecting a year-on-year decrease of 10.05%, with a gross profit margin of 64.60% [1]